FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2465702436> ?p ?o ?g. }

• W2465702436 endingPage "2041" @default.
• W2465702436 startingPage "2041" @default.
• W2465702436 abstract "Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients Bruno Amato,1,2,* Rita Compagna,1,2,* Aldo Rocca,2 Tommaso Bianco,2 Marco Milone,2 Luigi Sivero,2 Gabriele Vigliotti,2 Maurizio Amato,2 Michele Danzi,2 Giovanni Aprea,2 Luca Gallelli,3,* Stefano de Franciscis,1,4,* Raffaele Serra1,4,* 1Interuniversity Center of Phlebolymphology, International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, Viale Europa, Catanzaro, 2Department of Clinical Medicine and Surgery, University of Naples “Federico II”, Naples, 3Department of Health Sciences, 4Department of Medical and Surgical Sciences, University of Catanzaro, Catanzaro, Italy *These authors contributed equally to this work Introduction: In cancer patients, the chest computer tomography (CT) can be used to identify asymptomatic pulmonary embolism (APE). In most cases, these patients are treated with anticoagulant drugs for at least 3 months. The American College of Physicians recommend treatment of these patients as patients with symptomatic pulmonary embolism. In this study, we evaluated and compared the efficacy and safety of fondaparinux vs warfarin in the prevention of unsuspected pulmonary embolism in patients with active cancer. Materials and methods: A prospective and parallel group study was performed on 64 cancer patients (29 males and 35 females) with APE. A multidetector CT angiography with high spatial and temporal resolution and quality of arterial opacification was used to make the diagnosis. Lung scintigraphy was reserved to selected patients only. Patients were randomized to either the warfarin (Group A) or the fondaparinux (Group B) for 90 days. The first end point of efficacy was the persistence, reduction, or disappearance of thrombosis after 90 days. The second end point was the reappearance of thrombosis after 1 year. The first end point of safety was the development of major bleeding. Results: We enrolled 32 patients into each treatment group. We reached the first end point of efficacy and safety in Group B which showed that fondaparinux was able to induce the disappearance of thrombotic pulmonary with a lower incidence of major bleeding events compared with warfarin. No difference in the secondary end point was recorded. Conclusion: We suggest that the treatment of cancer patients with APE can be oriented with the administration of a standard dose of fondaparinux until the next CT lung control (3 months). However, the lack of a randomized clinical trial, including a larger patient cohort, does not allow formulation of final recommendations in these patients. A broader study would be desirable, involving a larger number of patients and a longer follow-up period. Keywords: cancer patients, asymptomatic pulmonary embolism, fondaparinux, warfarin" @default.
• W2465702436 created "2016-07-22" @default.
• W2465702436 creator A5002882515 @default.
• W2465702436 creator A5007107310 @default.
• W2465702436 creator A5008045147 @default.
• W2465702436 creator A5008542209 @default.
• W2465702436 creator A5019272410 @default.
• W2465702436 creator A5023347140 @default.
• W2465702436 creator A5029283436 @default.
• W2465702436 creator A5031682840 @default.
• W2465702436 creator A5033841937 @default.
• W2465702436 creator A5035172498 @default.
• W2465702436 creator A5044784746 @default.
• W2465702436 creator A5075153102 @default.
• W2465702436 creator A5088751003 @default.
• W2465702436 date "2016-06-01" @default.
• W2465702436 modified "2023-10-17" @default.
• W2465702436 title "Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients" @default.
• W2465702436 cites W1493835275 @default.
• W2465702436 cites W1588253900 @default.
• W2465702436 cites W1602511043 @default.
• W2465702436 cites W1634950970 @default.
• W2465702436 cites W1671277730 @default.
• W2465702436 cites W1750674640 @default.
• W2465702436 cites W1873218418 @default.
• W2465702436 cites W1968499632 @default.
• W2465702436 cites W1969803003 @default.
• W2465702436 cites W1984833612 @default.
• W2465702436 cites W2000924272 @default.
• W2465702436 cites W2009310269 @default.
• W2465702436 cites W2015247134 @default.
• W2465702436 cites W2025711232 @default.
• W2465702436 cites W2037052545 @default.
• W2465702436 cites W2055925611 @default.
• W2465702436 cites W2061227527 @default.
• W2465702436 cites W2065276135 @default.
• W2465702436 cites W2069238101 @default.
• W2465702436 cites W2075196907 @default.
• W2465702436 cites W2108416990 @default.
• W2465702436 cites W2131099415 @default.
• W2465702436 cites W2135635656 @default.
• W2465702436 cites W2139721320 @default.
• W2465702436 cites W2166046225 @default.
• W2465702436 cites W2176095570 @default.
• W2465702436 cites W2230876598 @default.
• W2465702436 cites W2272247547 @default.
• W2465702436 cites W99605343 @default.
• W2465702436 doi "https://doi.org/10.2147/dddt.s106153" @default.
• W2465702436 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4922788" @default.
• W2465702436 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27382257" @default.
• W2465702436 hasPublicationYear "2016" @default.
• W2465702436 type Work @default.
• W2465702436 sameAs 2465702436 @default.
• W2465702436 citedByCount "16" @default.
• W2465702436 countsByYear W24657024362016 @default.
• W2465702436 countsByYear W24657024362017 @default.
• W2465702436 countsByYear W24657024362018 @default.
• W2465702436 countsByYear W24657024362019 @default.
• W2465702436 countsByYear W24657024362020 @default.
• W2465702436 countsByYear W24657024362021 @default.
• W2465702436 countsByYear W24657024362022 @default.
• W2465702436 countsByYear W24657024362023 @default.
• W2465702436 crossrefType "journal-article" @default.
• W2465702436 hasAuthorship W2465702436A5002882515 @default.
• W2465702436 hasAuthorship W2465702436A5007107310 @default.
• W2465702436 hasAuthorship W2465702436A5008045147 @default.
• W2465702436 hasAuthorship W2465702436A5008542209 @default.
• W2465702436 hasAuthorship W2465702436A5019272410 @default.
• W2465702436 hasAuthorship W2465702436A5023347140 @default.
• W2465702436 hasAuthorship W2465702436A5029283436 @default.
• W2465702436 hasAuthorship W2465702436A5031682840 @default.
• W2465702436 hasAuthorship W2465702436A5033841937 @default.
• W2465702436 hasAuthorship W2465702436A5035172498 @default.
• W2465702436 hasAuthorship W2465702436A5044784746 @default.
• W2465702436 hasAuthorship W2465702436A5075153102 @default.
• W2465702436 hasAuthorship W2465702436A5088751003 @default.
• W2465702436 hasBestOaLocation W24657024361 @default.
• W2465702436 hasConcept C121608353 @default.
• W2465702436 hasConcept C126322002 @default.
• W2465702436 hasConcept C141071460 @default.
• W2465702436 hasConcept C2776256026 @default.
• W2465702436 hasConcept C2776265017 @default.
• W2465702436 hasConcept C2776301958 @default.
• W2465702436 hasConcept C2776877702 @default.
• W2465702436 hasConcept C2777185221 @default.
• W2465702436 hasConcept C2779161974 @default.
• W2465702436 hasConcept C2780868729 @default.
• W2465702436 hasConcept C2991741193 @default.
• W2465702436 hasConcept C71924100 @default.
• W2465702436 hasConceptScore W2465702436C121608353 @default.
• W2465702436 hasConceptScore W2465702436C126322002 @default.
• W2465702436 hasConceptScore W2465702436C141071460 @default.
• W2465702436 hasConceptScore W2465702436C2776256026 @default.
• W2465702436 hasConceptScore W2465702436C2776265017 @default.
• W2465702436 hasConceptScore W2465702436C2776301958 @default.
• W2465702436 hasConceptScore W2465702436C2776877702 @default.
• W2465702436 hasConceptScore W2465702436C2777185221 @default.
• W2465702436 hasConceptScore W2465702436C2779161974 @default.

• next